Close Menu

NEW YORK – Castle Biosciences reported after the close of the market on Tuesday that its fourth quarter revenues rose 54 percent year over year.

For the three months ended Dec. 31, 2019, the skin cancer diagnostics company reported revenues of $17.6 million, up from $11.4 million a year earlier, and beating the average Wall Street estimate of $11.7 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.